Literature DB >> 1622988

Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen.

T Zerbe1, B Uretsky, R Kormos, J Armitage, T Wolyn, B Griffith, R Hardesty, R Duquesnoy.   

Abstract

Graft atherosclerosis after heart transplantation is a problem that may limit long-term survival. The objective of this study was to establish whether an association exists between graft atherosclerosis, cellular rejection, HLA compatibility, or antilymphocyte antibodies in recipient serum. Results of cineangiograms from 306 recipients were available. Life table and logistic regression analysis identified only a significant effect of cellular rejection on development of angiogram-evident graft vessel disease. A total of 146 allografts obtained at another transplantation or autopsy were also available. Coronary vessel narrowing was measured by planimetry. Linear regression with coronary narrowing as dependent variable established a positive association with history of cellular rejection. No effect was documented for panel reactive antibody level obtained before or after transplantation. We also did not show an impact of HLA mismatch on this process. The lack of HLA antigen effect prompts us to be cautious about linking graft atherosclerosis directly to the rejection event.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622988

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma.

Authors:  H Nagano; P Libby; M K Taylor; S Hasegawa; J L Stinn; G Becker; N L Tilney; R N Mitchell
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

2.  Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection.

Authors:  Tengfang Li; Zhongqiang Zhang; Joe G Bartolacci; Gaelen K Dwyer; Quan Liu; Lisa R Mathews; Murugesan Velayutham; Anna S Roessing; Yoojin C Lee; Helong Dai; Sruti Shiva; Martin H Oberbarnscheidt; Jenna L Dziki; Steven J Mullet; Stacy G Wendell; James D Wilkinson; Steven A Webber; Michelle Wood-Trageser; Simon C Watkins; Anthony J Demetris; George S Hussey; Stephen F Badylak; Hēth R Turnquist
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 3.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

Review 4.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

5.  Smooth muscle cell proliferation but not neointimal formation is dependent on alloantibody in a murine model of intimal hyperplasia.

Authors:  B Soleimani; A Katopodis; G Wieczorek; A J T George; P I Hornick; C Heusser
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

6.  Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-alpha and proliferate during acute rejection of rabbit cardiac allografts.

Authors:  H Tanaka; S J Swanson; G Sukhova; F J Schoen; P Libby
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

7.  Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts.

Authors:  Jonathan C Choy; Alexandra Kerjner; Brian W Wong; Bruce M McManus; David J Granville
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

8.  Modification of alternative messenger RNA splicing of fibroblast growth factor receptors in human cardiac allografts during rejection.

Authors:  X M Zhao; W H Frist; T K Yeoh; G G Miller
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.